statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in...

Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Annovis Bio in a research note issued to investors on Tuesday...

HC Wainwright Comments on Annovis Bio, Inc.'s Q1 2025 Earnings (NYSE:ANVS)

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ( Annovis or the Company ), a clinical-stage drug platform company developing novel therapies for neurodegenerative...

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Over the last three days, A.I.dvisor has detected that ANVS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Annovis Bio (ANVS, $11.96) Aroon Indicator entered an Uptrend on April 01, 2024.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Annovis Bio announces publication on buntanetap

Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company...

Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans

Annovis Bio (ANVS, $11.9) Aroon Indicator entered an Uptrend on March 28, 2024.

This is a signal that ANVS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Annovis Bio (ANVS, $11.31) RSI Indicator left the overbought zone on March 22, 2024

Annovis Bio (ANVS, $11.83) RSI Indicator left the overbought zone on March 21, 2024

Annovis Bio falls -9.0%

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Volume	609,601.00
52-Wk High	$22.49
52-Wk Low	$4.86

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.83	--	--	N/A
Q4'23	-$1.51	--	--	N/A
Q3'23	-$1.09	-$1.63	-49.54%	MISSED
Q2'23	-$1.14	-$1.07	6.14%	BEAT
Q1'23	-$0.59	-$1.19	-100.95%	MISSED

ANVS Annovis Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals